Market size, share and growth analysis by product type, application and end user, across all major regions and key countries, with forecasts for 2024–2033. The competitive landscape profiles 20+ companies.
The global cardiac troponin market was valued at USD 1.6 Bn in 2024 and is projected to reach USD 4.2 Bn by 2033, growing at a CAGR of 12.6%. Europe is the largest regional market and Asia-Pacific is growing fastest.
Global Cardiac Market was valued at USD 1.6 Billion in 2024 and is expected to reach USD 4.2 Billion by 2033, at a CAGR of 12.6% during the forecast period 2024 - 2033.
Source: Custom Market Insights analysis.
To learn more about this report - request a sample report PDF
Troponin, a protein complex present in skeletal and cardiac muscle fibres, regulates muscular contraction. Troponin levels in the blood are elevated, which indicates myocardial damage or heart muscle tension.
Cardiac Market Growth Factors
Rising incidence of cardiovascular disease
The increased frequency of cardiovascular diseases (CVDs) has been a major driver in the troponin industry. Troponin is a cardiac biomarker used to diagnose acute myocardial infarction (AMI), a form of heart attack that is frequently related to cardiovascular diseases.
As the global incidence of CVDs grows, so does the demand for troponin testing. Troponin tests identify myocardial damage with high sensitivity and specificity, enabling early diagnosis and appropriate management in patients with suspected AMI.
Furthermore, advances in troponin testing methods have resulted in the creation of high-sensitivity troponin tests, which enhance diagnostic accuracy and clinical results. As a result, the rising incidence of CVDs emphasises the need for troponin testing in clinical practice, propelling the troponin market to fulfil the rising demand for diagnostic solutions in cardiovascular care.
The researchers merged data from the 2020 US Census Bureau report for the years 2025 to 2060 with the frequency of cardiovascular risk factors or illness from the US National Health and Nutrition Examination Survey.
From 2025 to 2060, all four CV risk factors are anticipated to rise in the general US population, with diabetes leading the way (39.3% increase to 55 million people), followed by dyslipidemia (27.6% to 126 million), hypertension (25.1% to 162 million), and obesity (18.3% to 126 million).
Technological advancements in troponin testing
Technological improvements in troponin testing are transforming the industry by increasing the accuracy, sensitivity, and speed of cardiac biomarker identification. Newer troponin tests use high-sensitivity methods that allow the identification of even trace levels of troponin proteins generated after myocardial damage.
These tests have quick turnaround times, enabling the early detection of acute myocardial infarction (AMI) and better patient outcomes. Furthermore, developments in point-of-care testing equipment and automation have streamlined testing operations, lowering time-to-results and enabling rapid clinical decision-making.
Moreover, the use of digital technologies that include cloud-based data management platforms and mobile health applications allows for real-time data sharing, remote monitoring, and statistical analysis, which improves the efficiency and efficacy of troponin testing in clinical practice.
Roche has gained 510(k) approval for its Elecsys Troponin T Gen 5 STAT (TnT Gen 5 STAT) blood test for acute heart attacks. With its approval, Roche became the first IVD business in the United States to offer next-generation Troponin testing to patients as a tool in the diagnosis of myocardial infarction, allowing doctors to more correctly identify patients having a heart attack.
Cardiac Troponin Market: Restraints
High cost of tests
The high cost of testing is a considerable barrier to entry into the troponin business, inhibiting widespread acceptance and limiting market expansion. Troponin tests are critical for detecting disorders like myocardial infarction and evaluating heart function.
However, many healthcare practitioners and patients continue to be concerned about their affordability, especially in resource-constrained areas. The high cost of diagnostic tests limits access, resulting in inequities in healthcare delivery and patient outcomes.
Furthermore, healthcare facilities may suffer cost limits in obtaining troponin testing equipment and reagents, worsening the situation. Efforts to minimise prices through technical innovation, bulk purchase agreements, and government subsidies might assist in alleviating this issue and increase access to troponin testing.
Furthermore, improved awareness of the need for early identification and therapy of cardiac conditions may drive demand for troponin tests, incentivizing stakeholders to address cost barriers and foster market growth.
Cardiac Troponin Market: Opportunities
Increasing adoption of point-of-care testing
The troponin market is expanding as more people use point-of-care testing (POCT). POCT enables quick and convenient testing of biomarkers such as troponin at the patient's bedside or in ambulatory settings, delivering instantaneous findings without the need for centralised laboratory facilities.
This tendency is especially noticeable in emergency rooms, critical care units, and outpatient clinics, where prompt diagnostic and treatment choices are vital. Troponin testing is critical in the diagnosis and treatment of acute myocardial infarction (heart attack), as high troponin levels signal cardiac muscle injury.
With the increase in cardiovascular disorders and the need for rapid and reliable diagnostic tools, there is a rising need for troponin assays that are compatible with POCT devices. Companies are aiming to manufacture portable, user-friendly troponin tests that deliver rapid results, driving the expansion of the troponin market in conjunction with the wider adoption of POCT technology.
As POC assays can provide troponin results within 20 min and can be used proximate to patient care, improvements in the efficiency of assessment of patients with suspected acute coronary syndrome are possible, particularly with new high-sensitivity assays.
Cardiac Troponin Market: Segmentation Analysis
Global Troponin market is segmented by product type, application, end user and region. Based on product type, the market is classified into Troponin T, and Troponin I. Troponin I dominated the market in 2023 with a market share of 58.2% and is expected to keep its dominance during the forecast period 2024-2033.
Troponin I is a vital protein present in cardiac muscle cells, and its presence in the circulation is an important diagnostic sign for heart muscle injury, particularly in diseases such as heart attacks. As healthcare practitioners depend more on troponin testing to identify and monitor cardiac problems, the need for troponin assays and testing kits has increased.
Manufacturers are investing in R&D to increase troponin test sensitivity, specificity, and speed, which is fuelling market innovation. Furthermore, the increased global frequency of cardiovascular illnesses drives up demand for troponin testing, since early identification and management are critical to patient outcomes.
As a result, Troponin I's crucial role in identifying heart muscle injury has positioned it as a cornerstone of the troponin market's growth and expansion.
Based on application, the market is classified into acute coronary syndrome, myocardial infarction, congestive heart failure, and others. Acute Coronary Syndrome dominated the market in 2023 with a market share of 45.5% and is expected to keep its dominance during the forecast period 2024-2033.
Acute Coronary Syndrome (ACS) is a medical disorder characterised by inadequate blood flow to the heart, which is frequently caused by the blockage of coronary arteries. Troponin, a protein secreted into the circulation after cardiac muscle injury, is critical in identifying ACS.
The rising need for troponin tests in ACS diagnosis has moved the troponin market forward. Troponin tests are used by healthcare practitioners to correctly diagnose myocardial damage and determine the severity of an ACS.
As the worldwide number of ACS cases rises due to reasons such as ageing populations, sedentary lifestyles, and the rising incidence of risk factors such as diabetes and hypertension, the need for troponin tests is predicted to increase. This has resulted in advances in troponin testing technology, including high-sensitivity tests.
Based on application, the market is classified into hospitals, diagnostic center, and homecare setting. Hospital dominated the market in 2023 with a market share of 61.8% and is expected to keep its dominance during the forecast period 2024-2033.
Hospitals play an important role in growing the troponin market by providing diagnosis and treatment regimens for cardiac diseases. Because troponin is an important biomarker for measuring heart damage, hospitals routinely use troponin testing in emergency rooms, cardiac care units, and outpatient clinics to detect acute myocardial infarction (heart attack) and other cardiac disorders.
Hospitals require troponin tests from diagnostic manufacturers to enable accurate and fast identification of cardiac events, allowing for immediate intervention and patient care. Furthermore, hospitals frequently perform research and clinical trials to assess the efficacy of novel troponin tests and procedures, which influence market trends and adoption rates.
Furthermore, hospitals collaborate with healthcare providers, insurance firms, and regulatory agencies to create reimbursement policies and standards for troponin testing, which influences market dynamics.
Report Scope
| Feature of the Report | Details |
| Market Size in 2024 | USD 1.6 Billion |
| Projected Market Size in 2033 | USD 4.2 Billion |
| Market Size in 2023 | USD 1.3 Billion |
| CAGR Growth Rate | 12.6% CAGR |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Key Segment | By Product Type, Application, End User and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Troponin Market: Regional Analysis
By region, Troponin market is segmented into North America, Europe, Asia-Pacific, Latin America, Middle East & Africa. North America dominated the global Troponin market in 2023 with a market share of 41.1% and is expected to keep its dominance during the forecast period 2024-2033.
North America's healthcare system has enhanced diagnostic capabilities, resulting in a significant demand for troponin testing in the detection of acute coronary syndromes (ACS), myocardial infarctions (MI), and other cardiac diseases.
Furthermore, the prevalence of lifestyle-related risk factors that include obesity, sedentary lifestyle, and poor eating habits adds to a substantial burden of cardiovascular disease in the region, driving up demand for troponin assays.
Moreover, the presence of major manufacturers and research institutes in North America promotes innovation and development of troponin testing technologies, which drives market expansion. Furthermore, solid regulatory frameworks and reimbursement policies encourage the use of troponin tests in clinical practice, assuring their widespread availability and use across medical facilities.
Cardiac Troponin Market Recent Developments
List of the prominent players in the Cardiac Troponin Market:
These key players are adopting various growth strategies such as mergers & acquisitions, joint ventures, expansion, strategic alliances, new product launches, etc. to enhance their business operations and revenues.
The Cardiac Troponin Market is segmented as follows:
By Product Type
By Application
By End User
Regional Coverage:
North America
Europe
Asia Pacific
The Middle East & Africa
Latin America
Updated: January 2026 · Formats: PDF, Excel, PPT
The major driver for the Troponin market is rising incidence of the cardiovascular disease and technological advancements in troponin testing.
The "Acute Coronary Syndrome" had the largest share in the global market for Troponin.
The "Troponin T" category dominated the market in 2023.
The key players in the market are Abbott Laboratories, Siemens Healthineers, Roche Diagnostics, Beckman Coulter, bioMérieux SA, Ortho Clinical Diagnostics, Bio-Rad Laboratories, Thermo Fisher Scientific, Randox Laboratories, Merck KGaA, PerkinElmer, Becton, Dickinson and Company , Sekisui Diagnostics, Luminex Corporation, Fujirebio, DiaSorin S.p.A, Singulex Inc., Tosoh Corporation, Mindray Bio-Medical Electronics Co. Ltd., Shenzhen YHLO Biotech Co. Ltd., Others.
"North America" had the largest share in the Troponin Market.
The global market is projected to grow at a CAGR of 12.6% during the forecast period, 2024-2033.
The Troponin Market size was valued at USD 1.6 Billion in 2024.
Author · Sr. Research Analyst
Ayush Kadam is a Senior Market Research Analyst at Custom Market Insights, with over seven years of experience in syndicated and custom market research. He specializes in market sizing, competitive intelligence, industry trends, forecasting, and strategic insights, helping clients turn complex data into actionable business decisions.
Buy individual chapters for $490 each: 8 chapters available, from Executive Summary to Company Profiles.
Get the full report structure, sample pages and data tables in the free sample.
Download free sampleGet the full report structure, sample pages and data tables in the free sample.
Download free sampleGet the full report structure, sample pages and data tables in the free sample.
Download free sample